July 29 (Reuters) - GlaxoSmithKline PLC:
* GSK ANNOUNCES FDA APPROVAL FOR NUCALA (MEPOLIZUMAB) FOR USE IN ADULTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS Further company coverage:
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,734 GBX | +0.29% | +3.80% | +19.54% |
05-06 | GSK : UBS remains its Buy rating | ZD |
05-03 | GSK : DZ Bank remains Neutral | ZD |
July 29 (Reuters) - GlaxoSmithKline PLC:
* GSK ANNOUNCES FDA APPROVAL FOR NUCALA (MEPOLIZUMAB) FOR USE IN ADULTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS Further company coverage:
1st Jan change | Capi. | |
---|---|---|
+19.54% | 88.87B | |
+31.52% | 690B | |
+21.96% | 546B | |
-5.21% | 358B | |
+17.02% | 323B | |
+5.01% | 287B | |
+13.68% | 235B | |
+3.81% | 199B | |
-10.63% | 195B | |
+3.98% | 161B |